Technology -
Hardware, Equipment & Parts - NYSE - US
$ 0.1377
-4.38 %
$ 15.3 M
Market Cap
-0.69
P/E
1. INTRINSIC VALUE
Balance Sheet
Know Labs, Inc.
| Current Assets | 3.11 M |
| Cash & Short-Term Investments | 3.11 M |
| Receivables | 0 |
| Other Current Assets | 0 |
| Non-Current Assets | 554 K |
| Long-Term Investments | 0 |
| PP&E | 404 K |
| Other Non-Current Assets | 149 K |
| Current Liabilities | 5.16 M |
| Accounts Payable | 553 K |
| Short-Term Debt | 4.53 M |
| Other Current Liabilities | 77.6 K |
| Non-Current Liabilities | 657 K |
| Long-Term Debt | 657 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Know Labs, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 15.2 M |
| Operating Income | -15.2 M |
| Other Expenses | 1.36 M |
| Net Income | -16.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Know Labs, Inc.
| Net Income | -16.6 M |
| Depreciation & Amortization | 270 K |
| Capital Expenditures | -66.4 K |
| Stock-Based Compensation | 2.96 M |
| Change in Working Capital | -1.18 M |
| Others | 1.39 M |
| Free Cash Flow | -12.9 M |
Wall Street Analysts Price Targets
Know Labs, Inc.
KNW has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
KNW does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Know Labs, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Mar 24, 2023
|
Sell 4.4 K
USD
|
Takesako Ichiro John Paul
Director
|
- 5000
|
0.8795 USD |
|
1 year ago
Mar 27, 2023
|
Sell 4.62 K
USD
|
Takesako Ichiro John Paul
Director
|
- 5000
|
0.924 USD |
|
1 year ago
Mar 28, 2023
|
Sell 4.5 K
USD
|
Takesako Ichiro John Paul
Director
|
- 5000
|
0.8993 USD |
|
1 year ago
Mar 29, 2023
|
Sell 4.51 K
USD
|
Takesako Ichiro John Paul
Director
|
- 5000
|
0.9011 USD |
|
1 year ago
Mar 30, 2023
|
Sell 6.18 K
USD
|
Takesako Ichiro John Paul
Director
|
- 7120
|
0.8684 USD |
|
1 year ago
Mar 30, 2023
|
Sell 1.22 K
USD
|
Takesako Ichiro John Paul
Director
|
- 1380
|
0.8876 USD |
|
1 year ago
Mar 31, 2023
|
Sell 6.6 K
USD
|
Takesako Ichiro John Paul
Director
|
- 7500
|
0.8801 USD |
|
1 year ago
Mar 29, 2023
|
Bought
4.59 K USD
|
English Jessica
Chief Marketing Officer
|
+ 5000
|
0.9186 USD |
|
1 year ago
Mar 16, 2023
|
Bought
164 USD
|
OWENS WILLIAM ARTHUR
Director
|
+ 200
|
0.8201 USD |
|
1 year ago
Mar 16, 2023
|
Bought
19.3 K USD
|
OWENS WILLIAM ARTHUR
Director
|
+ 23500
|
0.8201 USD |
|
1 year ago
Mar 16, 2023
|
Bought
492 USD
|
OWENS WILLIAM ARTHUR
Director
|
+ 600
|
0.8202 USD |
|
1 year ago
Mar 16, 2023
|
Bought
4.06 K USD
|
PEPPER JON
Director
|
+ 5000
|
0.8126 USD |
|
1 year ago
Mar 15, 2023
|
Bought
4.24 K USD
|
ERICKSON RONALD P
Director
|
+ 5000
|
0.849 USD |
|
1 year ago
Mar 15, 2023
|
Bought
5.04 K USD
|
Trautwein Leonardo Mouta
Chief Marketing Officer
|
+ 6000
|
0.8399 USD |
7. News
Know Labs, Inc. Announces $300K Registered Direct Offering
SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. Announces $300K Registered Direct Offering.
businesswire.com
- 1 month ago
Know Labs, Inc. Announces Receipt of Audit Opinion with Going Concern Explanation
SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), leading developer of non-invasive diagnostics technology, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended September 30, 2024, which was filed on November 14, 2024 with the Securities and Exchange Commission, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company.
businesswire.com
- 2 months ago
Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2024 Results
SEATTLE--(BUSINESS WIRE)--Know Labs, an emerging developer of non-invasive medical diagnostic technology, reported financial results for the Q4 and fiscal year of 2024.
businesswire.com
- 2 months ago
Know Labs Sensor Technology in Steering Wheels Could Curb Impaired Driving
SEATTLE--(BUSINESS WIRE)--Know Labs Sensor Technology in Steering Wheels Could Curb Impaired Driving. Know Labs Retains Stanbridge Group to Secure Automotive JV Partnerships.
businesswire.com
- 3 months ago
Know Labs Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
SEATTLE--(BUSINESS WIRE)--Know Labs Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards. A Plan for Compliance has been undertaken.
businesswire.com
- 3 months ago
Know Labs, Inc. (KNW) Q3 2024 Earnings Call Transcript
Know Labs, Inc. (NYSE:KNW ) Q3 2024 Results Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Ron Erickson - Chairman and Chief Executive Officer Peter Conley - Chief Financial Officer and Senior Vice President, IP Conference Call Participants Operator Greetings. Welcome to Know Labs's Third Quarter 2024 Earnings Conference Call.
seekingalpha.com
- 5 months ago
Know Labs, Inc. Reports Third Quarter FY 2024 Results
SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter of the fiscal year 2024 ended June 30, 2024. Financial Highlights: In Q3 FY 2024, Know Labs reported a net loss of $4.10 million dollars, compared to a net loss of $3.60 million dollars in Q3 FY 2023, an increase in net loss of 13.9%. This translates to earnings per share of a loss of $0.05, better than the prio.
businesswire.com
- 5 months ago
Know Labs, Inc. Announces Closing of $3.445 Million Public Offering
SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostics technology, today announced the successful closing of its previously announced underwritten public offering of 13,250,000 units at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26, and the partial exercise of the underwriters' opt.
businesswire.com
- 5 months ago
Know Labs to Present at the American Diabetes Association's Scientific Sessions
SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today announced further interim results from a clinical research study that assessed the accuracy of Know Labs' proprietary non-invasive radiofrequency (RF) dielectric sensor in measuring blood glucose. Participants with prediabetes and Type 2 diabetes were studied and venous blood was used as a comparative reference. The study found that the accuracy of Know Labs'.
businesswire.com
- 6 months ago
Know Labs Joins the Industrial Participant Program of the Wyss Institute for Biologically Inspired Engineering at Harvard University
SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today announced that it has joined the Industrial Participant Program of the Wyss Institute for Biologically Inspired Engineering at Harvard University's Diagnostics Accelerator. The Wyss Institute at Harvard University is a translational research institute, developing disruptive innovation for healthcare and sustainability, powered by a multidisciplinary bioenginee.
businesswire.com
- 7 months ago
Know Labs Appoints Chris Somogyi as President, International
SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International. With over 40 years of experience in commercializing innovation across related industries, Somogyi brings a wealth of expertise to lead the Company's “Skunkworks” Program and global patent licensing efforts. In his role, Somogyi will focus on identifying new applications of Know Labs' extens.
businesswire.com
- 8 months ago
Know Labs, Inc. (KNW) Q2 2024 Earnings Call Transcript
Know Labs, Inc. (NYSE:KNW ) Q2 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jordyn Hujar - Chief of Staff Ron Erickson - Chief Executive Officer Peter Conley - Chief Financial Officer Conference Call Participants Operator Greetings. Welcome to Know Labs's Second Quarter 2024 Earnings Conference Call.
seekingalpha.com
- 8 months ago
8. Profile
Summary
Know Labs, Inc. KNW
COUNTRY
US
INDUSTRY
Hardware, Equipment & Parts
MARKET CAP
$ 15.3 M
Dividend Yield
0.00%
Description
Know Labs, Inc. focuses on the development and commercialization of proprietary technologies in the United States. Its technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a molecular signature. The company refers to its technology as Bio-RFID. The Bio-RFID technology can be integrated into various wearable, mobile, or bench-top form factors. Its first application of Bio-RFID technology is a product marketed as a glucose monitor that provide the user with real time information on their blood glucose levels. The company was formerly known as Visualant, Incorporated and changed its name to Know Labs, Inc. in May 2018. Know Labs, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
Contact
500 Union Street, Seattle, WA, 98101
https://www.knowlabs.co
IPO
Date
April 18, 2006
Employees
15
Officers
Dr. Dominic Klyve Ph.D.
Chief Science Officer
Dr. John Cronin
Interim Chief Technology Officer & Independent Director
Jordyn Hujar
Chief of Staff
Mr. Leonardo Trautwein
Chief Commercial Officer
Mr. Ronald P. Erickson J.D.
Founder, Chief Executive Officer, Treasurer & Chairman
Dr. James H. Anderson Jr., M.D.
Chief Medical Officer and Chairman of Medical, Scientific & Regulatory Advisory Board
Mr. Peter Joseph Conley
Chief Financial Officer & Senior Vice President of Intellectual Property